Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
J Appl Clin Med Phys ; 25(2): e14157, 2024 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-37820316

RESUMO

Radioembolization using Yttrium-90 (90 Y) microspheres is widely used to treat primary and metastatic liver tumors. The present work provides minimum practice guidelines for establishing and supporting such a program. Medical physicists play a key role in patient and staff safety during these procedures. Products currently available are identified and their properties and suppliers summarized. Appropriateness for use is the domain of the treating physician. Patient work up starts with pre-treatment imaging. First, a mapping study using Technetium-99m (Tc-99m ) is carried out to quantify the lung shunt fraction (LSF) and to characterize the vascular supply of the liver. An MRI, CT, or a PET-CT scan is used to obtain information on the tumor burden. The tumor volume, LSF, tumor histology, and other pertinent patient characteristics are used to decide the type and quantity of 90 Y to be ordered. On the day of treatment, the appropriate dose is assayed using a dose calibrator with a calibration traceable to a national standard. In the treatment suite, the care team led by an interventional radiologist delivers the dose using real-time image guidance. The treatment suite is posted as a radioactive area during the procedure and staff wear radiation dosimeters. The treatment room, patient, and staff are surveyed post-procedure. The dose delivered to the patient is determined from the ratio of pre-treatment and residual waste exposure rate measurements. Establishing such a treatment modality is a major undertaking requiring an institutional radioactive materials license amendment complying with appropriate federal and state radiation regulations and appropriate staff training commensurate with their respective role and function in the planning and delivery of the procedure. Training, documentation, and areas for potential failure modes are identified and guidance is provided to ameliorate them.


Assuntos
Embolização Terapêutica , Neoplasias Hepáticas , Humanos , Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada , Microesferas , Neoplasias Hepáticas/radioterapia , Radioisótopos de Ítrio/uso terapêutico , Embolização Terapêutica/métodos , Física
2.
Med Dosim ; 37(3): 257-64, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22365418

RESUMO

Twenty-three targets in 16 patients treated with stereotactic radiosurgery (SRS) or stereotactic body radiotherapy (SBRT) were analyzed in terms of dosimetric homogeneity, target conformity, organ-at-risk (OAR) sparing, monitor unit (MU) usage, and beam-on time per fraction using RapidArc volumetric-modulated arc therapy (VMAT) vs. multifield sliding-window intensity-modulated radiation therapy (IMRT). Patients underwent computed tomography simulation with site-specific immobilization. Magnetic resonance imaging fusion and optical tracking were incorporated as clinically indicated. Treatment planning was performed using Eclipse v8.6 to generate sliding-window IMRT and 1-arc and 2-arc RapidArc plans. Dosimetric parameters used for target analysis were RTOG conformity index (CI(RTOG)), homogeneity index (HI(RTOG)), inverse Paddick Conformity Index (PCI), D(mean) and D5-D95. OAR sparing was analyzed in terms of D(max) and D(mean). Treatment delivery was evaluated based on measured beam-on times delivered on a Varian Trilogy linear accelerator and recorded MU values. Dosimetric conformity, homogeneity, and OAR sparing were comparable between IMRT, 1-arc RapidArc and 2-arc RapidArc plans. Mean beam-on times ± SD for IMRT and 1-arc and 2-arc treatments were 10.5 ± 7.3, 2.6 ± 1.6, and 3.0 ± 1.1 minutes, respectively. Mean MUs were 3041, 1774, and 1676 for IMRT, 1-, and 2-arc plans, respectively. Although dosimetric conformity, homogeneity, and OAR sparing were similar between these techniques, SRS and SBRT fractions treated with RapidArc were delivered with substantially less beam-on time and fewer MUs than IMRT. The rapid delivery of SRS and SBRT with RapidArc improved workflow on the linac with these otherwise time-consuming treatments and limited the potential for intrafraction organ and patient motion, which can cause significant dosimetric errors. These clinically important advantages make image-guided RapidArc useful in the delivery of SRS and SBRT to intracranial and extracranial targets.


Assuntos
Neoplasias Encefálicas/diagnóstico por imagem , Neoplasias Encefálicas/radioterapia , Radiometria/métodos , Radiocirurgia/métodos , Planejamento da Radioterapia Assistida por Computador/métodos , Radioterapia Guiada por Imagem/métodos , Tomografia Computadorizada por Raios X/métodos , Adulto , Idoso , Feminino , Humanos , Pessoa de Meia-Idade , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Resultado do Tratamento , Adulto Jovem
3.
Med Phys ; 33(7): 2598-609, 2006 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-16898464

RESUMO

The delivery accuracy of radiation therapy for pulmonary and abdominal tumors suffers from tumor motion due to respiration. Respiratory gating should be applied to avoid the use of a large target volume margin that results in a substantial dose to the surrounding normal tissue. Precise respiratory gating requires the exact spatial position of the tumor to be determined in real time during treatment. Usually, fiducial markers are implanted inside or next to the tumor to provide both accurate patient setup and real-time tumor tracking. However, current tumor tracking systems require either substantial x-ray exposure to the patient or large fiducial markers that limit the value of their application for pulmonary tumors. We propose a real-time tumor tracking system using implanted positron emission markers (PeTrack). Each marker will be labeled with low activity positron emitting isotopes, such as 124I, 74As, or 84Rb. These isotopes have half-lives comparable to the duration of radiation therapy (from a few days to a few weeks). The size of the proposed PeTrack marker will be 0.5-0.8 mm, which is approximately one-half the size of markers currently employed in other techniques. By detecting annihilation gammas using position-sensitive detectors, multiple positron emission markers can be tracked in real time. A multimarker localization algorithm was developed using an Expectation-Maximization clustering technique. A Monte Carlo simulation model was developed for the PeTrack system. Patient dose, detector sensitivity, and scatter fraction were evaluated. Depending on the isotope, the lifetime dose from a 3.7 MBq PeTrack marker was determined to be 0.7-5.0 Gy at 10 mm from the marker. At the center of the field of view (FOV), the sensitivity of the PeTrack system was 240-320 counts/s per 1 MBq marker activity within a 30 cm thick patient. The sensitivity was reduced by 45% when the marker was near the edge of the FOV. The scatter fraction ranged from 12% (124I, 74As) to 16% (84Rb). In addition, four markers (labeled with 124I) inside a 30 cm diameter water phantom were simulated to evaluate the feasibility of the multimarker localization algorithm. Localization was considered successful if a marker was localized to within 2 mm from its true location. The success rate of marker localization was found to depend on the number of annihilation events used and the error in the initial estimate of the marker position. By detecting 250 positron annihilation events from 4 markers (average of 62 events per marker), the marker success rates for initial errors of +/-5, +/-10, and +/-15 mm were 99.9%, 99.6%, and 92.4%, respectively. Moreover, the average localization error was 0.55 (+/-0.27) mm, which was independent of initial error. The computing time for localizing four markers was less than 20 ms (Pentium 4, 2.8 GHz processor, 512 MB memory). In conclusion, preliminary results demonstrate that the PeTrack technique can potentially provide real-time tumor tracking with low doses associated with the marker's activity. Furthermore, the small size of PeTrack markers is expected to facilitate implantation and reduce patient risk.


Assuntos
Neoplasias/radioterapia , Próteses e Implantes , Planejamento da Radioterapia Assistida por Computador/métodos , Algoritmos , Braquiterapia/instrumentação , Braquiterapia/métodos , Simulação por Computador , Humanos , Método de Monte Carlo , Movimento , Aceleradores de Partículas , Imagens de Fantasmas , Espalhamento de Radiação , Sensibilidade e Especificidade , Software , Fatores de Tempo
4.
Gynecol Oncol ; 99(1): 84-91, 2005 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-16109440

RESUMO

OBJECTIVE(S): To determine the feasibility of integrating an in vitro chemo-radiation response assay (IVRRA) with a gene microarray system to investigate the molecular patterns of expression that contribute to radiation resistance in cervical cancer. METHODS: Viable primary untreated cervical cancer specimens were obtained and exposed to gamma irradiation at a dose of 3 Gy in the IVRRA to determine in vitro radiation sensitivity. RNA was purified for microarray analysis with the Affymetrix Human Genome U95A Array carrying more than 12,000 gene probes. Gene expression analysis was performed, and specimen transcript patterns were correlated with radiation response using an iteration analysis model and Pearson's correlation coefficient. RESULTS: A feasibility set of eight tumor specimens was studied. Tumors were classified into 4 extreme (ERR), 2 intermediate (IRR) and 2 low radiation resistance (LRR) categories. An intrinsic radiation response gene set of 54 genes transcripts with 100% accuracy for the classification of each tumor's radiation response category was identified. CONCLUSION(S): Gene sets associated with in vitro radiation response profiles in cervical cancer can be generated using the IVRRA and microarray technology. This has direct applications to the study of the biological pathways contributing to radiation resistance and may lead to the development of alternative treatment modalities. The potential of these technologies for cancers in which radiotherapy is employed warrants further investigation.


Assuntos
Tolerância a Radiação/genética , Neoplasias do Colo do Útero/tratamento farmacológico , Neoplasias do Colo do Útero/radioterapia , Estudos de Viabilidade , Feminino , Perfilação da Expressão Gênica , Humanos , Estadiamento de Neoplasias , Análise de Sequência com Séries de Oligonucleotídeos , RNA Neoplásico/genética , RNA Neoplásico/isolamento & purificação , Neoplasias do Colo do Útero/patologia
5.
Am Surg ; 70(11): 947-53, 2004 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-15586503

RESUMO

This is a retrospective analysis of a new treatment modality, intra-arterial administration of Yttrium-90 TheraSphere, for unresectable hepatocellular carcinoma (HCC). Patients with HCC not amenable to surgical treatment who had satisfactory physiological function without comorbid disease or significant pulmonary shunting were eligible for treatment. Patients were categorized into complete, partial, or no response based on serum alpha-fetoprotein (AFP) levels and CT or MRI imaging. Fourteen patients were considered candidates for treatment. Three patients were excluded due to significant hepatopulmonary shunting. Eleven patients were treated with TheraSphere. One patient (9%) had a complete response, eight patients (78%) had a partial response, and two patients (18%) showed no response. Partial and complete responders with AFP-associated HCC demonstrated a median decrease in AFP levels of 79 per cent at 73 days. No patients developed liver toxicity nor died due to treatment. Five patients (45%) died of progressive disease at a median of 7 months post-treatment. Six patients (54%) were alive at a median of 11 months (range, 9 to 20 months). Okuda stage 2 and 3 patients showed a median survival of 11 months and 7 months, respectively. Yttrium-90 TheraSphere treatment for unresectable hepatocellular carcinoma is well tolerated and appears to extend survival.


Assuntos
Braquiterapia/métodos , Carcinoma Hepatocelular/terapia , Neoplasias Hepáticas/terapia , Radioisótopos de Ítrio/administração & dosagem , Idoso , Carcinoma Hepatocelular/radioterapia , Cateterismo , Feminino , Artéria Hepática , Humanos , Neoplasias Hepáticas/radioterapia , Masculino , Microesferas , Pessoa de Meia-Idade , Dosagem Radioterapêutica , Estudos Retrospectivos , Resultado do Tratamento , Radioisótopos de Ítrio/uso terapêutico
6.
Med Phys ; 31(8): 2344-55, 2004 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-15377101

RESUMO

As compared with multi-leaf collimator based intensity modulated radiation therapy (IMRT) techniques, physical modulators have the major advantage of temporally invariant intensity map delivery which makes it more flexible with monitor unit rate, simpler resolution of interrupted treatment and easier implementation and use with respiratory gating. However, traditional physical modulator techniques require long fabrication time and operator intervention during treatments. It has been previously proposed [Xu et al., Med. Phys. 29, 2222-2229 (2002)] that a reshapeable automatic intensity modulator (RAIM) can automatically produce physical modulators by molding a deformable high x-ray attenuation material using a matrix of computer-controlled pistons. RAIM can potentially eliminate the limitations of traditional physical modulators. The present study addresses the treatment planning considerations of RAIM for IMRT. In this study, a 3D treatment-planning system (PLUNC) was modified to include the capability of providing treatment planning using RAIM. Two clinically representative cases were studied: nasopharyngeal and prostate tumors. First, the RAIM system with two different spatial resolutions at isocenter, 1 x 1 cm2 and 0.5 x 0.5 cm2, were evaluated. The treatment planning results of RAIM were then compared with other IMRT techniques such as smooth modulator with ideal (100%-2%) and limited (100%-13%) intensity modulation ranges, segmental multi-leaf collimator (SMLC) with ten intensity levels, 1 cm leaf width and 0.5 cm step size and serial tomotherapy using the Peacock system. Bringing the spatial resolution of RAIM down to 0.5 x 0.5 cm2 did not show improvement due to the effect of penumbra. The RAIM system with 1 x 1 cm2 proved slightly inferior as compared to the ideal smooth physical modulator but better than the SMLC technique and the smooth modulator with limited modulation range. When compared to serial tomotherapy, RAIM is only inferior in brain stem sparing for the nasopharynx case. Furthermore, the RAIM system with 1 x 1 cm2 resolution required significantly lower monitor units as compared to the other IMRT techniques for the two cases studied.


Assuntos
Algoritmos , Neoplasias Nasofaríngeas/radioterapia , Neoplasias da Próstata/radioterapia , Planejamento da Radioterapia Assistida por Computador , Humanos , Masculino
7.
Med Dosim ; 27(2): 171-6, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-12074469

RESUMO

The purpose of this work is to evaluate our initial experience in treating previously irradiated, recurrent head-and-neck cancers using intensity-modulated radiotherapy (IMRT). Between July 1997 and September 1999, 12 patients with previously irradiated, locally recurrent head-and-neck cancers were treated with IMRT. These included cancers of the nasopharynx, oropharynx, hypopharynx, larynx, paranasal sinus, skin of the head-and-neck region, and malignant melanoma. Five of these 12 patients had received radiation as the primary treatment, with doses ranging from 66.0 to 126.0 Gy, and the remaining 7 patients had undergone definitive surgeries followed by an adjuvant course of radiation treatment, with doses ranging between 36.0 and 64.8 Gy. Recurrence after the initial course of radiation occurred in periods ranging from 4 to 35 months, with 11 of 12 cases recurring fully in the fields of previous irradiation. Recurrent tumors were treated with IMRT to total doses between 30 to 70 Gy (> 50 Gy in 10 cases) prescribed at the 75% to 92% isodose lines with daily fractions of 1.8 to 2 Gy. The results revealed that acute toxicities were acceptable except in 1 patient who died of aspiration pneumonia during the course of retreatment. There were 4 complete responders, 2 partial responders, and 2 patients with stable disease in the IMRT-treated volumes. Three patients received IMRT as adjuvant treatment following salvage surgery. At 4 to 16 months of follow-up, 7 patients were still alive, with 5 revealing no evidence of disease. In conclusion, this pilot study demonstrates that IMRT offers a viable mode of re-irradiation for recurrent head-and-neck cancers in previously irradiated sites. Longer follow-up time and a larger number of patients are needed to better define the therapeutic advantage of IMRT in recurrent, previously irradiated head-and-neck cancers.


Assuntos
Carcinoma de Células Escamosas/radioterapia , Carcinoma/radioterapia , Neoplasias de Cabeça e Pescoço/radioterapia , Melanoma/radioterapia , Recidiva Local de Neoplasia/radioterapia , Planejamento da Radioterapia Assistida por Computador , Radioterapia Conformacional , Adulto , Idoso , Carcinoma/diagnóstico por imagem , Carcinoma de Células Escamosas/diagnóstico por imagem , Feminino , Seguimentos , Neoplasias de Cabeça e Pescoço/diagnóstico por imagem , Humanos , Masculino , Melanoma/diagnóstico por imagem , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/diagnóstico por imagem , Avaliação de Resultados em Cuidados de Saúde , Dosagem Radioterapêutica , Retratamento , Tomografia Computadorizada por Raios X
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA